Onsdag 27 November | 08:33:09 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-11-06 13:30 Kvartalsrapport 2025-Q3
2025-08-21 13:30 Kvartalsrapport 2025-Q2
2025-05-08 13:30 Kvartalsrapport 2025-Q1
2025-02-27 08:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-16 - X-dag ordinarie utdelning STENO 0.00 DKK
2024-05-15 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-22 - Bokslutskommuniké 2023
2024-02-05 - Extra Bolagsstämma 2024
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-20 - Kvartalsrapport 2023-Q1
2023-06-13 - Extra Bolagsstämma 2023
2023-05-22 - X-dag ordinarie utdelning STENO 0.00 DKK
2023-02-23 - Bokslutskommuniké 2022
2022-11-18 - Extra Bolagsstämma 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning STENO 0.00 DKK
2022-05-19 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-24 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning STENO 0.00 DKK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-25 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning STENO 0.00 DKK
2020-05-14 - Årsstämma
2020-05-07 - Kvartalsrapport 2020-Q1
2020-02-26 - Bokslutskommuniké 2019
2019-11-06 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-07 - Kvartalsrapport 2019-Q1
2019-02-21 - Bokslutskommuniké 2018

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriLäkemedel & Handel
Stenocare är verksamt inom hälsovårdsindustrin. Bolaget är specialiserat inom utveckling av medicinsk cannabis. Stenocare är en av de första aktören att ha påbörjat försäljning av medicinska cannabisoljor i Danmark. Bolaget kommer framöver även vända sig till övriga europeiska marknader med sitt produktutbud. Stenocares huvudkontor ligger i Randers.
2023-12-29 12:11:16

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER:  STENO

The promise: On November 29, 2023, STENOCARE announced the decision to amend the terms relating to the now completed exercise of TO1 Warrants. As part of this, the set minimum (and maximum) price for exercise of the TO1 warrant was removed. This was done to honor the promises of a 30% discount to all TO1 subscribers made at the time of the rights issue in June 2023.

The Compensation Offer: The announcement on November 29, 2023 also included an offer for compensation for TO1 Warrant owners that would realise a loss due to the amended terms. Stenocare announced compensation details on December 6. The offer is for TO1 Warrants owners that 1) sold TO1 warrants before November 29, then 2) repurchased warrants at a loss after November 29 and 3) also exercised these warrants before December 19, 2023. In summary:
  • Condition #1: The warrant holder must have sold warrants of TO1 between 20 June 2023, 9.00 AM (CEST) and 29 November 2023, 4.41 PM (CET)
  • Condition #2: The warrant holder must have purchased TO1 warrants  between 29 November 2023, 4.42 PM (CET) and 15 December 2023, 5.00 PM (CET)
  • Condition #3:  Compensation is given if the warrant holder has realized a loss (ie. purchase price minus sales price)
  • Condition #4: The warrant holder must have exercised the number of warrants of series TO1 between 6 December 2023, 9.00 AM (CET) and 19 December 2023, 5.00 PM (CET) that is being requested for compensation.
  • Detailed terms apply and full bank documentation for related transactions is required. See link below.

The procedure: The TO1 Warrant exercise period has ended, and Stenocare shareholders who fulfill the requirements for the TO1 Warrant compensation ref. above must download, fill in, sign and submit the "Compensation Request Form" from https://stenocare.com/compensation/ on the Stenocare investor page no later than January 12, 2024. Stenocare will process eligible shareholders requests and transfer compensation payments by end of January 2024.